ORIGINAL RESEARCH article
Front. Med.
Sec. Pulmonary Medicine
Doxycycline Treatment for Drug-Resistant Mycoplasma pneumoniae Pneumonia and Evaluation of Key Predictive Factors for Refractory Disease
Ruijuan Ren
Yuping Xu
Xinyan Cui
Mengsheng Zhang
Xiangtao Wu
Tuanjie Wang
Xue Liu
Shu-Jun Li
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Objective: Mycoplasma pneumoniae pneumonia (MPP) in children is a common respiratory infection, with rising concerns over macrolide-resistant strains. The aim of this study is to establish an effective diagnostic prediction model for refractory MPP (RMPP) and evaluate doxycycline as an alternative treatment for macrolide-unresponsive MPP (MUMPP). Methods: 106 children with RMPP receiving doxycycline and 73 children with MUMPP treated with azithromycin were retrospectively analyzed. For all patients, the detection of MP-DNA in BALF, alongside clinical criteria, served to confirm active MP infection and infer phenotypic macrolide unresponsiveness/resistance. Univariate and multivariate logistic regression analyses were then used to identify clinically available risk factors for the development of RMPP among these patients with MP pneumonia. Results: The doxycycline group had significantly shorter fever duration, fewer lavage procedures, reduced steroid use, and shorter hospital stays compared to the azithromycin group (P < 0.05). Multivariate analysis identified four independent risk factors for RMPP: duration of macrolide use before admission, days of fever before hospitalization, procalcitonin (PCT), and C-reactive protein (CRP). A nomogram based on these factors showed excellent discrimination, with an AUC of 0.982 (95% CI: 0.961–1.000). The calibration curve approached the 45-degree line, and decision curve analysis (DCA) indicated that the nomogram provided positive net benefit across a reasonable range of threshold probabilities, supporting its potential clinical utility. Conclusion: In children with MUMPP, doxycycline treatment is associated with superior clinical outcomes compared to azithromycin. A nomogram incorporating readily available clinical factors can effectively identify patients at risk of developing RMPP, supporting early intervention.
Summary
Keywords
Diagram, Doxycycline, Mycoplasma, Refractory pneumonia, resistant
Received
28 September 2025
Accepted
20 January 2026
Copyright
© 2026 Ren, Xu, Cui, Zhang, Wu, Wang, Liu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shu-Jun Li
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.